Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: LLLefty who wrote (225)	7/9/1998 1:20:00 PM
From: Doug	Respond to of 340

LLLefly: Looks like the beating is nearing the end. The street does not like being let down repeatedly. The Mgmt appears to have learnt a lesson and may be less arrogant in future.

To: LLLefty who wrote (225)	7/9/1998 1:21:00 PM
From: Doug	Respond to of 340

LLLefly: Looks like the beating is nearing the end. The street does not like being let down repeatedly. The Mgmt appears to have learnt a lesson and may be less arrogant in future.

To: LLLefty who wrote (225)	7/9/1998 2:55:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 340

I also think Teva now represents a good opportunity. Management should still be viewed with suspicion, but the company makes money and its products are selling well. COP-1, although not a very effective MS treatment, is the only real alternative to interferon treatments and is pulling many betaseron takers away from Schering. It's trading at 15X the past 4 quarters' earnings: pretty attractive relative to the rest of the market. If the company can stop talking and just quietly put up good numbers, Teva stock should appreciate nicely.